Five Prime Therapeutics Names Bryan Irving, Ph.D. as Chief Scientific Officer
18 May 2018 - - South San Francisco, California-based protein drug discovery specialist Five Prime Therapeutics, Inc. (NASDAQ: FPRX) has appointed Bryan Irving, Ph.D., as executive vice president and chief scientific officer, the company said.
Irving joined Five Prime in August 2017 as the vice president of research. Prior to joining Five Prime, he was at CytomX Therapeutics, where he most recently served as vice president of cancer immunology.
Irving received a Ph.D. in Immunology from the University of California, San Francisco and a B.A. in Physiology from the University of California, Berkeley.
Five Prime Therapeutics discovers and develops therapeutics to improve the lives of patients with serious diseases.
The company's comprehensive extracellular protein discovery platform positions it to explore pathways in cancer, inflammation, and their intersection in immuno-oncology, an area of growing focus of the company's R and D activities.